Tyrphostins and other tyrosine kinase inhibitors

Annual Review of Biochemistry

Volumn 75, Issue , 2006, Pages 93-109

  Levitzki, Alexander ^a   Mishani, Eyal ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cancer therapy; Signal transduction; Tyrosine phosphorylation; Tyrphostin

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; ADENOSINE TRIPHOSPHATE; ALPHA (3,4 DIMETHOXYBENZYLIDENE) 2 PYRIDYLACETONITRILE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CANERTINIB; CETUXIMAB; CG 1295; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; INTERLEUKIN 12; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3 INHIBITOR; JANUS KINASE INHIBITOR; LIGAND; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; SORAFENIB; SUNITINIB; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

APOPTOSIS; CANCER; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IMMUNOPATHOLOGY; MOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; GRAFT OCCLUSION, VASCULAR; HUMANS; JANUS KINASE 2; JANUS KINASE 3; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC; MOLECULAR STRUCTURE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TYRPHOSTINS;

EID: 33746347333     PISSN: 00664154     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.biochem.75.103004.142657     Document Type: Review

References (110)

1. Levitzki A. 1994. Eur. J. Biochem. 226:1-13
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002. Science 98:1912-34
3. Levitzki A. 1990. Biochem. Pharmacol. 40:913-18
4. Hanks SK, Quinn AM, Hunter T. 1988. Science 241:42-52
5. Graziani Y, Erikson E, Erikson RL. 1983. Eur. J. Biochem. 135:583-89
6. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, et al. 1987. J. Biol. Chem. 262:5592-95
7. Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, et al. 1986. J. Antibiot. 39:170-73
8. Onoda T, Iinuma H, Sasaki Y, Hamada M, Isshiki K, et al. 1989. J. Nat. Prod. 52:1252-57
9. Levitzki A. 1992. FASEB J. 6:3275-82
10. Levitzki A. 1999. Pharmacol. Ther. 82:231-39
11. Klein S, McCormick F, Levitzki A. 2005. Nat. Rev. Cancer 5:573-80
12. Levitzki A, Gazit A. 1995. Science 267:1782-88
13. Klein S, Levitzki A. 2006. Curr. Signal Transduct. Ther. 1:1-12
14. Shechter Y, Yaish P, Chorev M, Gilon C, Braun S, Levitzki A. 1989. EMBO J. 8:1671-76
15. Yaish P. 1988. Synthetic inhibitors for tyrosine kinase. PhD thesis. The Hebrew Univ., Jerusalem. 125 pp.
16. Yaish P, Gazit A, Gilon C, Levitzki A. 1988. Science 242:933-35
17. Gazit A, Yaish P, Gilon C, Levitzki A. 1989. J. Med. Chem. 32:2344-52
18. Yoneda T, Lyall RM, Alsina MM, Persons PE, Spada AP, et al. 1991. Cancer Res. 51:4430-35
19. Vasella D, Slater R. 2003. In Magic Cancer Bullet-How a Tiny Orange Pill May Rewrite Medical History. New York: HarperCollins
20. Posner I, Engel M, Gazit A, Levitzki A. 1994. Mol. Pharmacol. 45:673-83
21. Osherov N, Gazit A, Gilon C, Levitzki A. 1993. J. Biol. Chem. 268:11134-42
22. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, et al. 1994. Cancer Res. 54:6106-14
23. Gazit A, Osherov N, Posner I, Bar-Sinai A, Gilon C, Levitzki A. 1993. J. Med. Chem. 36:3556-64
24. Anafi M, Gazit A, Gilon C, Ben-Neriah Y, Levitzki A. 1992. J. Boil. Chem. 267:4518-23
25. Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, et al. 1999. Blood 93:3973-82
26. Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, et al. 2002. Blood 99:664-71
27. Anafi M, Gazit A, Zehavi A, Ben-Neriah Y, Levitzki A. 1993. Blood 82:3524-29
28. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. 1996. Nat. Med. 2:561-66
29. Blanke CD, Corless CL. 2005. Cancer Investig. 23:274-80
30. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, et al. 2005. Cancer Res. 65:4500-5
31. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. 2000. Science 289:1938-42
32. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. 2004. Science 305:399-401
33. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, et al. 2005. Cancer Cell 7:129-41
34. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. 2004. Nat. Med. 10:1187-89
35. Donate NJ, Wu JY, Stapley J, Gallick G, Lin H, et al. 2003. Blood 101:690-98
36. Gadzicki D, von Neuhoff N, Steinemann D, Just M, Busche G, et al. 2005. Cancer Genet. Cytogenet. 159:164-67
37. Doggrell SA. 2005. Expert Opin. Investig. Drugs 14:89-91
38. Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, et al. 2005. Proc. Natl. Acad. Sci. USA 102:1992-97
39. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, et al. 2003. Blood 101:664-72
40. Levitzki A, Bohmer FD. 1998. Anticancer Drug Des. 13:731-34
41. Levitzki A. 2000. In Topics in Current Chemistry, pp. 1-15. Berlin/Heidelberg: Springer-Verlag
42. Livnah N, Levitzki A, Senderovitz H, Yechezkel T, Salitra Y, et al. 2004. Patent Coop. Treaty WO 204/110337 A2
43. Blum G, Gazit A, Levitzki A. 2000. Biochemistry 39:15705-12
44. Blum G, Gazit A, Levitzki A. 2003. J. Biol. Chem. 278:40442-54
45. Ward WH, Cook PN, Slater AM, Davies DH, Holdgate GA, Green LR. 1994. Biochem. Pharmacol. 48:659-66
46. Osherov N, Levitzki A. 1994. Eur. J. Biochem. 225:1047-53
47. Wakeling AE. 2002. Curr. Opin. Pharmacol. 2:382-87
48. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, et al. 2005. J. Clin. Oncol. 23:6829-37
49. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. 2004. Science 304:1497-500
50. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. 2004. N. Engl. J. Med. 350:2129-39
51. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, et al. 2005. Proc. Natl. Acad. Sci. USA 102:7665-70
52. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, et al. 2005. N. Engl. J. Med. 353:2012-24
53. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. 2005. PLoS Med. 2:e73
54. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, et al. 2005. PLoS Med. 2:e17
55. Bonasera TA, Ortu G, Rozen Y, Krais R, Freedman NM, et al. 2001. Nucl. Med. Biol. 28:359-74
56. DeJesus OT, Murali D, Flores LG, Converse AK, Dick DW, et al. 2003. J. Label. Compd. Radiopharm. 46 (Suppl. 1):S1-9
57. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, et al. 1998. Proc. Natl. Acad. Sci. USA 95:12022-27
58. Tsou HR, Mamuya N, Johnson BD, Reich MF, Gruber BC, et al. 2001. J. Med. Chem. 44:2719-34
59. Discafani CM, Carroll ML, Floyd MB Jr, Hollander IJ, Husain Z, et al. 1999. Biochem. Pharmacol. 57:917-25
60. Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, et al. 2000. Cancer Chemother. Pharmacol. 45:231-38
61. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, et al. 2004. Cancer Res. 64:3958-65
62. Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, et al. 2000. J. Med. Chem. 43:1380-97
63. Smaill JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, et al. 2001. J. Med. Chem. 44:429-40
64. Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, et al. 2004. Bioorg. Med. Chem. 12:3421-29
65. Mishani E, Abourheh G, Jacobson O, Dissoki S, Daniel RB, et al. 2005. J. Med. Chem. 48:5337-48
66. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, et al. 2003. J. Med. Chem. 46:49-63
67. Denny WA. 2002. Pharmacol. Ther. 93:253-61
68. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, et al. 2004. Clin. Cancer Res. 10:6487-501
69. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. 2004. Cancer Res. 64:5355-62
70. Tsai CM, Levitzki A, Wu LH, Chang KT, Cheng CC, et al. 1996. Cancer Res. 56:1068-74
71. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. 1998. Proc. Natl. Acad. Sci. USA 95:5724-29
72. Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, et al. 2001. J. Neurosurg. 95:472-79
73. Tamura K, Fukuoka M. 2005. Expert Opin. Pharmacother. 6:985-93
74. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, et al. 2002. Cancer Res. 62:4236-43
75. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. 1999. Mol. Cell 3:639-48
76. Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, et al. 1999. Struct. Fold. Des. 7:651-61
77. Karni R, Mizrachi S, Reiss-Sklan E, Gazit A, Livnah O, Levitzki A. 2003. FEBS Lett. 537:47-52
78. Dvorak HF. 2003. Am. J. Pathol. 162:1747-57
79. Robinson DR, Wu YM, Lin SF. 2000. Oncogene 19:5548-57
80. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, et al. 1996. Cancer Res. 56:3540-45
81. McTigue MA, Wickersham JA, Pinko C, Showalter RE, Parast CV, et al. 1999. Struct. Fold. Des. 7:319-30
82. Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, et al. 1999. J. Med. Chem. 42:5369-89
83. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, et al. 2002. Cancer Res. 62:4645-55
84. McCarty MF, Wey J, Stoeltzing O, Liu W, Fan F, et al. 2004. Mol. Cancer Ther. 3:1041-48
85. Sun L, Tran N, Liang C, Tang F, Rice A, et al. 1999. J. Med. Chem. 42:5120-30
86. Sun L, Tran N, Tang F, App H, Hirth P, et al. 1998. J. Med. Chem. 41:2588-603
87. Fong TA, Shawver LK, Sun L, Tang C, App H, et al. 1999. Cancer Res. 59:99-106
88. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, et al. 2000. Cancer Res. 60:4152-60
89. O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, et al. 2003. Clin. Cancer Res. 9:5465-76
90. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, et al. 2005. Blood 105:986-93
91. Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CDM, et al. 2004. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Presented at ASCO Annu. Meet. Proc., New Orleans
92. Lyons JF, Wilhelm S, Hibner B, Bollag G. 2001. Endocr. Relat. Cancer 8:219-25
93. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. 2004. Cancer Res. 64:7099-109
94. van Spronsen DJ, de Weijer KJ, Mulders PF, De Mulder RH. 2005. Anticancer Drugs 16:709-17
95. Ostman A. 2004. Cytokine Growth Factor Rev. 15:275-86
96. Ostman A, Heldin CH. 2001. Adv. Cancer Res. 80:1-38
97. Levitzki A. 2004. Cytokine Growth Factor Rev. 15:229-35
98. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, et al. 1995. Proc. Natl. Acad. Sci. USA 92:2558-62
99. Gazit A, Yee K, Uecker A, Bohmer FD, Sjoblom T, et al. 2003. Bioorg. Med. Chem. 11:2007-18
100. Kovalenko M, Ronnstrand L, Heldin CH, Loubtchenkov M, Gazit A, et al. 1997. Biochemistry 36:6260-69
101. Banai S, Gertz SD, Gavish L, Chorny M, Ferez LS, et al. 2004. Cardiovasc. Res. 64:165-71
102. Banai S, Wolf Y, Colomb G, Pearle A, Waltenberger J, et al. 1998. Circulation 97:1960-69
103. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. 2005. N. Engl. J. Med. 352:1779-90
104. Verma A, Kambhampati S, Parmar S, Platanias LC. 2003. Cancer Metastasis Rev. 22:423-34
105. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, et al. 1996. Nature 379:645-48
106. Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, et al. 2002. Mol. Cancer Ther. 1:893-99
107. Grunberger T, Demin P, Rounova O, Sharfe N, Cimpean L, et al. 2003. Blood 102:4153-58
108. Gu L, Zhuang H, Safina B, Xiao XY, Bradford WW, Rich BE. 2005. Bioorg. Med. Chem. 13:4269-78
109. Cetkovic-Cvrlje M, Uckun FM. 2004. Arch. Immunol. Ther. Exp. 52:69-82
110. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, et al. 2003. Science 302:875-78